Sunshine
Biopharma's Newly Designed mRNA Molecules Prove Effective Against
Multidrug Resistant Cancer Cells
A
Potential Multi-Billion Dollar Global Market Opportunity
for
Cancer
Treatments
Montreal, Quebec, Canada -- April
5, 2022 -- InvestorsHub NewsWire -- Sunshine Biopharma, Inc.
(NASDAQ: "SBFM" and "SBFMW"), a pharmaceutical company
focused on the research, development and commercialization of
oncology and antiviral drugs, today announced that two of its newly
designed mRNA molecules are effective at destroying cancer cells
grown in culture.
The cytotoxicity tests were
performed on a variety of cancer cells including multidrug
resistant breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma
cells (OVCAR-3), and pancreatic cancer cells (SUIT-2). Toxicity
studies using non-transformed (normal) human cells (HMEC cells)
showed that these mRNA molecules had little or no cytotoxic
effects. These new mRNA molecules are readily adaptable for
delivery into patients using the mRNA vaccine technology. The
Company anticipates filing a patent application in connection with
these results soon.
"We are delighted by these findings
in connection with our ongoing mRNA-as-therapeutic-agents
research," said Dr. Steve Slilaty, CEO of Sunshine Biopharma. "The
potential use of mRNA to treat cancer opens the door to many
possibilities for patients including convenience, reduced toxicity
and enhanced efficacy," he added.
About Sunshine
Biopharma
Severe Acute Respiratory
Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the
ongoing COVID-19 pandemic that has claimed the lives of over 6.1
million people worldwide since it first appeared in December 2019.
Sunshine Biopharma is working on the development of a treatment for
COVID-19 and has completed the synthesis of four potential
inhibitors of PLpro and subsequently identified a lead compound,
SBFM-PL4.
In addition, the Company recently
expanded its research efforts into finding other PLpro inhibitors
by entering into a collaboration agreement with the University of
Arizona.
The collaboration is focused on
determining the in vivo safety, pharmacokinetics, and dose
selection properties of three University of Arizona owned PLpro
inhibitors, followed by efficacy testing in mice infected with
SARS-CoV-2. The Company holds the first option to negotiate for a
commercial, royalty-bearing license for all intellectual property
developed by University of Arizona under the research
project.
In addition to working on the
development of a treatment for COVID-19, Sunshine Biopharma is
engaged in the development of Adva-27a, a unique anticancer
compound. Tests conducted to date have demonstrated the
effectiveness of Adva-27a at destroying Multidrug Resistant Cancer
Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer
cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical
trials for Pancreatic Cancer indication are planned to be conducted
at McGill University's Jewish General Hospital in Montreal, Canada.
Sunshine Biopharma is owner of all patents and intellectual
property pertaining to Adva-27a.
Cautionary Note
Regarding Forward Looking Statements
This press
release and statements of the Company's management made in
connection therewith contain "forward-looking statements" (as
defined in Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended)
concerning future events. Words such as "may", "could", "expects",
"projects," "intends", "plans", "believes", "predicts",
"anticipates", "hopes", "estimates" and variations of such words
and similar expressions are intended to identify forward-looking
statements. These statements appear in a number of places in this
release and include all statements that are not statements of
historical fact. These statements involve known and unknown risks
and are based upon several assumptions and estimates, which are
inherently subject to significant uncertainties and contingencies,
many of which are beyond the Company's control. Actual results may
differ materially from those expressed or implied by such
forward-looking statements. Factors that could cause actual results
to differ materially include, but are not limited to, the risk
factors described in the Company's filings with the SEC. The
Company's SEC filings can be obtained free of charge on the SEC's
website at www.sec.gov. Except to the extent required by law,
Sunshine Biopharma, Inc. (the "Company") expressly disclaims any
obligations or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in the Company's expectations with respect
thereto or any change in events, conditions, or circumstances on
which any statement is based.
For Additional
Information:
Sunshine Biopharma Media
Contacts:
TraDigital IR
Direct Line:
917-633-8980
investors@sunshinebiopharma.com
Sunshine Biopharma Inc.
Contacts:
Camille Sebaaly, CFO
Direct Line:
514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com